PURPOSE: Besides chemotherapy drugs, a number of @entity1 -related factors (i.e., gender, age, history of @entity167 consumption, and/or motion @entity2704 ) may be used to calculate the risk for chemotherapy-induced @entity391 . We evaluated data with the intent of identifying a unique variable associated with delayed @entity391 in @entity1 receiving @entity7730 ( @entity7730 ). METHODS: From an ongoing research study, the @entity750 metabolite, @entity1130 ( @entity5581 ), @entity1011 , and @entity4757 were measured over a 72-h period in 25 @entity1 receiving @entity7730 . All @entity1 were treated with a 5- @entity750 -3 receptor antagonist plus @entity619 according to published guidelines; none received aprepitant prophylactically. Urine @entity5581 / @entity1011 and serum @entity4757 values were grouped according to the development (+) or absence (-) of delayed @entity391 . Baseline mean values associated with the two neurotransmitters were analyzed by analysis of variance. RESULTS: Eleven @entity1 developed moderate to severe delayed @entity391 ; the other 14 were symptom-free. The pretreatment log (mean @entity5581 / @entity1011 ) was 1.22 and 1.81 in the (+) and (-) @entity391 groups, respectively, p = 0.0049; the pretreatment log (mean @entity4757 ) for the same respective groups was 5.33 and 4.09 pg/mL, p > 0.05. The log (mean ratio of @entity4757 to @entity5581 / @entity1011 ) between-group difference in those with and without @entity391 was 4.53 and 2.52, respectively, p = 0.0002. The @entity5581 / @entity1011 and ratio of @entity4757 to @entity5581 / @entity1011 data were also used to determine cutoff points which resulted in the optimal predictive accuracy. CONCLUSIONS: These preliminary findings suggest that an elevated pretreatment ratio of @entity4757 to @entity5581 / @entity1011 >70 is associated with the development of delayed @entity391 induced by @entity7730 .

Identification of a novel marker associated with risk for delayed chemotherapy-induced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol'] @entity5581 :: ('MESH:D006897', 'Chemical') :: ['5-HIAA'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting', 'emesis'] @entity2704 :: ('MESH:D008881', 'Disease') :: ['sickness'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin', 'hydroxytryptamine'] @entity7730 :: ('MESH:D064146', 'Disease') :: ['MEC', 'moderately emetogenic chemotherapy'] @entity1130 :: ('CHEBI:27823', 'Chemical') :: ['5-hydroxyindole acetic acid'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity4757 :: ('6863', 'Gene') :: ['substance P']
@entity391 :: (MESH:D014839,Disease) :: ['vomiting']
